Skip to main content
SpringerLink
Log in

Hormone Replacement Therapy with Testosterone and the Vascular System

  • Reference work entry
  • First Online:
PanVascular Medicine

  • 152 Accesses

Abstract

The diagnosis and treatment of androgen deficiency in boys and adult men with classical syndromes of hypogonadism are well established. Older men show a progressive decline of total and free testosterone levels, which have been related to sexual, somatic, and psychological symptoms. Some comorbid diseases, such as obesity, metabolic syndrome, diabetes, and atherosclerosis, further accentuate age-related testosterone deficiency, also named late-onset hypogonadism. Epidemiological data indicate that late-onset hypogonadism can be considered a new marker of cardiovascular health and mortality. The diagnosis of this emergent condition is challenged by the limitations of laboratory methods, the lack of standardized age-dependent thresholds of testosterone concentrations, and the uncertainties about the clinical significance of the symptoms attributable to hypogonadism. Whether low testosterone is just a consequence of metabolic imbalance and/or cardiovascular disease or a contributory factor to the progression of atherosclerosis is currently unclear, but it is likely that a bidirectional effect between decreased testosterone concentrations and disease pathology exists. Current indications for testosterone replacement therapy are limited to men with consistent symptoms and signs, and clearly low levels of testosterone. Nevertheless, testosterone treatment, beyond their known physiological actions on sexual function, bone mineralization, and body composition, has demonstrated modest positive effects on insulin resistance, glycemic control, and lipid profile in some trials performed in hypogonadal men with metabolic syndrome and/or diabetes. Furthermore, acute and chronic effects of testosterone suggest a vasodilator action on coronary vessels. Periodic monitoring of patients will be necessary to assess the treatment outcome, to decide the need for continuing treatment, and to avoid adverse effects, especially erythrocytosis and prostate cancer. While the old paradigm of testosterone being a dangerous hormone for the heart is no longer valid, the available evidence on the benefits and long-term risks of testosterone replacement therapy is still limited, especially in older men, and more basic and clinical research is needed to expand our knowledge on the role and the possibilities of testosterone.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 649.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 549.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Abbreviations

BMI:

Body mass index

DHT:

Dihydrotestosterone

FT:

Free testosterone

HDL:

High-density lipoprotein

HOMA:

Homeostatic model assessment

IL-6:

Interleukin-6

LDL:

Low-density lipoprotein

LH:

Luteinizing hormone

LOH:

Late-onset hypogonadism

PADAM:

Partial androgen deficiency of the aging male

PSA:

Prostate-specific antigen

SHBG:

Sex hormone-binding globulin

SOCCs:

Store-operated Ca2+ channels

TDS:

Testosterone deficiency syndrome

Tfm:

Testicular-feminized mouse

TNF-α:

Tumor necrosis factor-α

TT:

Total testosterone

VOCCs:

Voltage-operated Ca2+ channels

References

  • Ajayi AA, Mathur R, Halushka PV (1995) Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation 91:2742–2747

    Article  CAS  PubMed  Google Scholar 

  • Aksut SV, Aksut G, Karamehmetoglu A, Oram E (1986) The determination of serum estradiol, testosterone and progesterone in acute myocardial infarction. Jpn Heart J 27:825–837

    Article  CAS  PubMed  Google Scholar 

  • Alexandersen P, Haarbo J, Byrialsen I, Lawaetz H, Christiansen C (1999) Natural androgens inhibit male atherosclerosis. A study in castrated, cholesterol fed rabbits. Circ Res 84:813–819

    Article  CAS  PubMed  Google Scholar 

  • Anderson FH, Francis RM, Faulkner K (1996) Androgen supplementation in eugonadal men with osteoporosis-effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone 18:171–177

    Article  CAS  PubMed  Google Scholar 

  • Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA (2011) Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 96:3007–3019

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Aversa A, Isidori AM, De Martino MU, Caprio M, Fabbrini E, Rocchietti-March M, Frajese G, Fabbri A (2000) Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin Endocrinol (Oxf) 53:517–522

    Article  CAS  Google Scholar 

  • Bagatell CJ, Bremner WJ (1996) Androgens in men – uses and abuses. N Engl J Med 334:707–714

    Article  CAS  PubMed  Google Scholar 

  • Baldo-Enzi G, Giada F, Zuliani G, Baroni L, Vitale E, Enzi G, Magnanini P, Fellin R (1990) Lipid and apoprotein modifications in body builders during and after self-administration of anabolic steroids. Metabolism 39:203–208

    Article  CAS  PubMed  Google Scholar 

  • Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S (2010) Adverse events associated with testosterone administration. N Engl J Med 363:109–122

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM, Task Force, Endocrine Society (2010) Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95:2536–2559

    Article  CAS  PubMed  Google Scholar 

  • Bhasin S, Pencina M, Jasuja GK, Travison TG, Coviello A, Orwoll E, Wang PY, Nielson C, Wu F, Tajar A, Labrie F, Vesper H, Zhang A, Ulloor J, Singh R, D’Agostino R, Vasan RS (2011) Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab 96:2430–2439

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Brand JS, van der Tweel I, Grobbee DE, Emmelot-Vonk MH, van der Schouw YT (2011) Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol 40:189–207

    Article  PubMed  Google Scholar 

  • Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S (2005) Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 60:1451–1457

    Article  PubMed  Google Scholar 

  • Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, Mammi C, Piepoli M, Fini M, Rosano GM (2009) Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 54:919–927

    Article  CAS  PubMed  Google Scholar 

  • Cohen PG (1999) The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone–estradiol shunt – a major factor in the genesis of morbid obesity. Med Hypotheses 52:49–51

    Article  CAS  PubMed  Google Scholar 

  • Corona G, Mannucci E, Schulman C, Petrone L, Mansani R, Cilotti A, Balercia G, Chiarini V, Forti G, Maggi M (2006) Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. Eur Urol 50:595–604

    Article  PubMed  Google Scholar 

  • Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A, Forti G, Mannucci E, Maggi M (2011a) Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 8:272–283

    Article  CAS  PubMed  Google Scholar 

  • Corona G, Monami M, Rastrelli G, Aversa A, Sforza A, Lenzi A, Forti G, Mannucci E, Maggi M (2011b) Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl 34:528–540

    Article  CAS  PubMed  Google Scholar 

  • Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A, Forti G, Mannucci E, Maggi M (2011c) Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 165:687–701

    Article  CAS  PubMed  Google Scholar 

  • Corrales JJ, Almeida M, Burgo R, Mories MT, Miralles JM, Orfao A (2006) Androgen-replacement therapy depresses the ex vivo production of inflammatory cytokines by circulating antigen-presenting cells in aging type-2 diabetic men with partial androgen deficiency. J Endocrinol 189:595–604

    Article  CAS  PubMed  Google Scholar 

  • Cunningham GR, Toma SM (2011) Clinical review: why is androgen replacement in males controversial? J Clin Endocrinol Metab 96:38–52

    Article  CAS  PubMed  Google Scholar 

  • Deenadayalu VP, White RE, Stallone JN, Gao X, Garcia AJ (2001) Testosterone relaxes coronary arteries by opening the large-conductance, calcium-activated potassium channel. Am J Physiol 281:H1720–H1727

    CAS  Google Scholar 

  • Ding EL, Song Y, Malik VS, Liu S (2006) Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 295:1288–1299

    Article  CAS  PubMed  Google Scholar 

  • English KM, Steeds RP, Jones TH, Diver MJ, Channer KS (2000) Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 102:1906–1911

    Article  CAS  PubMed  Google Scholar 

  • English KM, Jones RD, Jones TH, Morice AH, Channer KS (2002) Testosterone acts as a coronary vasodilator by a calcium channel antagonist action. J Endocrinol Invest 25:455–458

    Article  CAS  PubMed  Google Scholar 

  • Fernández-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori VM (2010) Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 95:2560–2575

    Article  PubMed  Google Scholar 

  • Fowler JE Jr, Whitmore WF Jr (1981) The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 126:372–375

    PubMed  Google Scholar 

  • Friedrich N, Völzke H, Rosskopf D, Steveling A, Krebs A, Nauck M, Wallaschofski H (2008) Reference ranges for serum dehydroepiandrosterone sulfate and testosterone in adult men. J Androl 29:610–617

    Article  CAS  PubMed  Google Scholar 

  • Giannoulis MG, Martin FC, Nair KS, Umpleby AM, Sonksen P (2012) Hormone replacement therapy and physical function in healthy older men. Time to talk hormones? Endocr Rev 33:314–377

    Article  CAS  PubMed  Google Scholar 

  • Giton F, Fiet J, Guéchot J, Ibrahim F, Bronsard F, Chopin D, Raynaud JP (2006) Serum bioavailable testosterone: assayed or calculated? Clin Chem 52:474–481

    Article  CAS  PubMed  Google Scholar 

  • Gray A, Feldman HA, McKinlay JB, Longcope C (1991) Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 73:1016–1025

    Article  CAS  PubMed  Google Scholar 

  • Haffner SM, Ksuhwaha RS, Foster DM, Applebaum-Bowden D, Hazzard WR (1983) Studies on the metabolic mechanism of reduced high density lipoprotein during anabolic steroid therapy. Metabolism 32:413–417

    Article  CAS  PubMed  Google Scholar 

  • Hall J, Jones RD, Jones TH, Channer KS, Peers C (2006) Selective inhibition of L-type Ca2+ channels in A7r5 cells by physiological levels of testosterone. Endocrinology 147:2675–2680

    Article  CAS  PubMed  Google Scholar 

  • Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR, Baltimore Longitudinal Study of Aging (2001) Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86:724–731

    Article  CAS  PubMed  Google Scholar 

  • Isidori AM, Caprio M, Stroll F, Moretti C, Frajese G, Isidori A, Fabbri A (1999) Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab 84:3673–3680

    CAS  PubMed  Google Scholar 

  • Jeppesen LL, Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS, Winther K (1996) Decreased serum testosterone in men with acute ischemic stroke. Arterioscler Thromb Vasc Biol 16:749–754

    Article  CAS  PubMed  Google Scholar 

  • Johannsson G, Gibney J, Wolthers T, Leung KC, Ho KK (2005) Independent and combined effects of testosterone and growth hormone on extracellular water in hypopituitary men. J Clin Endocrinol Metab 90:3989–3994

    Article  CAS  PubMed  Google Scholar 

  • Jones TH (2007) Testosterone associations with erectile dysfunction, diabetes and the metabolic syndrome. Eur Urol Suppl 6:847–857

    Article  CAS  Google Scholar 

  • Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, Morales AM, Volterrani M, Yellowlees A, Howell JD, Channer KS, TIMES2 Investigators (2011) Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 34:828–837

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F (2010) Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol 73:602–612

    Article  CAS  Google Scholar 

  • Kaufman JM, Vermeulen A (2005) The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 26:833–876

    Article  CAS  PubMed  Google Scholar 

  • Keating NL, O’Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24:4448–4456

    Article  CAS  PubMed  Google Scholar 

  • Kelly DM, Jones TH (2013a) Testosterone: a metabolic hormone in health and disease. J Endocrinol 217:R25–R45

    Article  CAS  PubMed  Google Scholar 

  • Kelly DM, Jones TH (2013b) Testosterone: a vascular hormone in health and disease. J Endocrinol 217:R47–R71

    Article  CAS  PubMed  Google Scholar 

  • Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, Welch A, Day N (2007) Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 116:2694–2701

    Article  CAS  PubMed  Google Scholar 

  • Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB (2006) Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 91:843–850

    Article  CAS  PubMed  Google Scholar 

  • Laughlin GA, Barrett-Connor E, Bergstrom J (2008) Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 93:68–75

    Article  CAS  PubMed  Google Scholar 

  • Lesser MA (1942) The treatment of angina pectoris with testosterone propionate; preliminary report. N Engl J Med 226:51–54

    Article  Google Scholar 

  • Maggio M, Lauretani F, Ceda GP, Bandinelli S, Ling SM, Metter EJ, Artoni A, Carassale L, Cazzato A, Ceresini G, Guralnik JM, Basaria S, Valenti G, Ferrucci L (2007) Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. Arch Intern Med 167:2249–2254

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH, Channer KS (2004) Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 90:871–876

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH, Channer KS (2006) Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 27:57–64

    Article  CAS  PubMed  Google Scholar 

  • Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH, Channer KS (2010) Low serum testosterone and increased mortality in men with coronary heart disease. Heart 96:1821–1825

    Article  CAS  PubMed  Google Scholar 

  • Mårin P, Holmäng S, Gustafsson C, Jönsson L, Kvist H, Elander A, Eldh J, Sjöström L, Holm G, Björntorp P (1993) Androgen treatment of abdominally obese men. Obes Res 1:245–251

    Article  PubMed  Google Scholar 

  • Mathur A, Malkin C, Saeed B, Muthusamy R, Jones TH, Channer K (2009) Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol 161:443–449

    Article  CAS  PubMed  Google Scholar 

  • Mohr BA, Guay AT, O’Donnell AB, McKinlay JB (2005) Normal, bound and non-bound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing study. Clin Endocrinol 62:64–73

    Article  CAS  Google Scholar 

  • Morgentaler A, Schulman C (2009) Testosterone and prostate safety. Front Horm Res 37:197–203

    Article  CAS  PubMed  Google Scholar 

  • Morris PD, Channer KS (2012) Testosterone and cardiovascular disease in men. Asian J Androl 14:428–435

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Musabak U, Bolu E, Ozata M, Oktenli C, Sengul A, Inal A, Yesilova Z, Kilciler G, Ozdemir IC, Kocar IH (2003) Gonadotropin treatment restores in vitro interleukin-1beta and tumour necrosis factor-alpha production by stimulated peripheral blood mononuclear cells from patients with idiopathic hypogonadotropic hypogonadism. Clin Exp Immunol 132:265–270

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nettleship JE, Jones TH, Channer KS, Jones RD (2007) Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect that is independent of the classic androgen receptor. Circulation 116:2427–2434

    Article  CAS  PubMed  Google Scholar 

  • Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, Beckman JA, Choueiri TK (2011) Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 306:2359–2366

    Article  CAS  PubMed  Google Scholar 

  • Nieminen MS, Rämö MP, Viitasalo M, Heikkilä P, Karjalainen J, Mäntysaari M, Heikkilä J (1996) Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Eur Heart J 17:1576–1583

    Article  CAS  PubMed  Google Scholar 

  • Phillips GB, Pinkernell BH, Jing TY (1994) The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb 14:701–706

    Article  CAS  PubMed  Google Scholar 

  • Pitteloud N, Hardin M, Dwyer AA, Valassi E, Yialamas M, Elahi D, Hayes FJ (2005) Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 90:2636–2641

    Article  CAS  PubMed  Google Scholar 

  • Pugh PJ, Jones TH, Channer KS (2003) Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J 24:909–915

    Article  CAS  PubMed  Google Scholar 

  • Pugh PJ, Jones RD, West JN, Jones TH, Channer KS (2004) Testosterone treatment for men with chronic heart failure. Heart 90:446–447

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Raynaud JP, Gardette J, Rollet J, Legros JJ (2013) Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment. BJU Int 111:880–890

    Article  CAS  PubMed  Google Scholar 

  • Rey RA, Grinspon RP, Gottlieb S, Pasqualini T, Knoblovits P, Aszpis S, Pacenza N, Stewart Usher J, Bergadá I, Campo SM (2013) Male hypogonadism: an extended classification based on a developmental, endocrine physiology-based approach. Andrology 1:3–16

    Article  CAS  PubMed  Google Scholar 

  • Roddam AW, Allen NE, Appleby P, Key TJ (2008) Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100:170–183

    Article  CAS  PubMed  Google Scholar 

  • Rosano GM, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, Monica PL, Bonfigli B, Volpe M, Chierchia SL (1999) Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 99:1666–1670

    Article  CAS  PubMed  Google Scholar 

  • Rosano GM, Sheiban I, Massaro R, Pagnotta P, Marazzi G, Vitale C, Mercuro G, Volterrani M, Aversa A, Fini M (2007) Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res 19:176–182

    Article  CAS  PubMed  Google Scholar 

  • Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H (2007) Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society Position Statement. J Clin Endocrinol Metab 92:405–413

    Article  CAS  PubMed  Google Scholar 

  • Ruige JB, Mahmoud AM, De Bacquer D, Kaufman JM (2011) Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart 97:870–875

    Article  CAS  PubMed  Google Scholar 

  • Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L (2011) Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 165:675–685

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Scragg JL, Jones RD, Channer KS, Jones TH, Peers C (2004) Testosterone is a potent inhibitor of L-type Ca21 channels. Biochem Biophys Res Commun 318:503–506

    Article  CAS  PubMed  Google Scholar 

  • Sewdarsen M, Vythilingum S, Jialal I, Desai RK (1990) Abnormalities in sex hormones are a risk factor for premature manifestation of coronary artery disease in South African Indian men. Atherosclerosis 83:111–117

    Article  CAS  PubMed  Google Scholar 

  • Shahani S, Braga-Basaria M, Basaria S (2008) Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 93:2042–2049

    Article  CAS  PubMed  Google Scholar 

  • Shigehara K, Sugimoto K, Konaka H, Iijima M, Fukushima M, Maeda Y, Mizokami A, Koh E, Origasa H, Iwamoto T, Namiki M (2011) Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. Aging Male 14:53–58

    Article  PubMed  Google Scholar 

  • Shores MM, Moceri VM, Gruenewald DA, Brodkin KI, Matsumoto AM, Kivlahan DR (2004) Low testosterone is associated with decreased function and increased mortality risk: a preliminary study of men in a geriatric rehabilitation unit. J Am Geriatr Soc 52:2077–2081

    Article  PubMed  Google Scholar 

  • Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR (2006) Low serum testosterone and mortality in male veterans. Arch Intern Med 166:1660–1665

    Article  CAS  PubMed  Google Scholar 

  • Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM (2012) Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 97:2050–2058

    Article  CAS  PubMed  Google Scholar 

  • Spratt DI, Bigos ST, Beitins I, Cox P, Longcope C, Orav J (1992) Both hyper- and hypogonadotropic hypogonadism occur transiently in acute illness: bio- and immunoactive gonadotropins. J Clin Endocrinol Metab 75:1562–1570

    CAS  PubMed  Google Scholar 

  • Strain GW, Zumoff B, Miller LK, Rosner W, Levit C, Kalin M, Hershcopf RJ, Rosenfeld RS (1988) Effect of massive weight loss on hypothalamic-pituitary-gonadal function in obese men. J Clin Endocrinol Metab 66:1019–1023

    Article  CAS  PubMed  Google Scholar 

  • Tajar A, Forti G, O’Neill TW, Lee DM, Silman AJ, Finn JD, Bartfai G, Boonen S, Casanueva FF, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Vanderschueren D, Huhtaniemi IT, Wu FC, EMAS Group (2010) Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab 95:1810–1818

    Article  CAS  PubMed  Google Scholar 

  • Taskinen MR (2007) Is the metabolic syndrome the main threat to human health in the twenty-first century? Arterioscler Throm Vasc Biol 27:2275

    Article  CAS  Google Scholar 

  • Tenover JL (1992) Effects of testosterone supplementation in the ageing male. J Clin Endocrinol Metab 75:1092–1098

    CAS  PubMed  Google Scholar 

  • Traish AM, Guay A, Feeley R, Saad F (2009a) The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl 30:10–22

    Article  CAS  PubMed  Google Scholar 

  • Traish AM, Saad F, Guay A (2009b) The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 30:23–32

    Article  CAS  PubMed  Google Scholar 

  • Tsai HK, D’Amico AV, Sadetsky N, Chen MH, Carroll PR (2007) Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99:1516–1524

    Article  PubMed  Google Scholar 

  • Vermeulen A, Verdonck L, Kaufman JM (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666–3672

    Article  CAS  PubMed  Google Scholar 

  • Vesper HW, Bhasin S, Wang C, Tai SS, Dodge LA, Singh RJ, Nelson J, Ohorodnik S, Clarke NJ, Salameh WA, Parker CR Jr, Razdan R, Monsell EA, Myers GL (2009) Interlaboratory comparison study of serum total testosterone [corrected] measurements performed by mass spectrometry methods. Steroids 74:498–503

    Article  CAS  PubMed  Google Scholar 

  • Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS (2004) Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography–tandem mass spectrometry. J Clin Endocrinol Metab 89:534–543

    Article  CAS  PubMed  Google Scholar 

  • Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC (2008) Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 159:507–514

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P (1999a) Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 100:1690–1696

    Article  CAS  PubMed  Google Scholar 

  • Webb CM, Adamson DL, de Zeigler D, Collins P (1999b) Effect of acute testosterone on myocardial ischaemia in men with coronary artery disease. Am J Cardiol 83:437–439

    Article  CAS  PubMed  Google Scholar 

  • Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Punab M, Boonen S, Vanderschueren D, European Male Aging Study Group (2008) Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 93:2737–2745

    Article  CAS  PubMed  Google Scholar 

  • Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT, EMAS Group (2010) Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 363:123–135

    Article  CAS  PubMed  Google Scholar 

  • Zirkin BR, Tenover JL (2012) Aging and declining testosterone: past, present, and hopes for the future. J Androl 33:1111–1118

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Further Reading

  • Kang HY (2013) Beyond the male sex hormone: deciphering the metabolic and vascular actions of testosterone. J Endocrinol 217:C1–C3. doi:10.1530/JOE-13-0052

    Article  CAS  PubMed  Google Scholar 

  • Surampudi PN, Wang C, Swerdloff R (2012) Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy. Int J Endocrinol 2012:625434. doi:10.1155/2012/625434

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Andrology Department, Fundació Puigvert, Universitat Autònoma de Barcelona, Cartagena, 340-350, 08025, Barcelona, Spain

    Lluís Bassas

  2. Endocrinology/Medicine Department, Hospital de Sant Pau, IIB-SantPau, CIBERER 747, Universitat Autònoma de Barcelona, Sant Antoni Maria Claret, 167, 08025, Barcelona, Spain

    Eugenia Resmini

Authors
  1. Lluís Bassas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eugenia Resmini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lluís Bassas .

Editor information

Editors and Affiliations

  1. Division of Cardiovascular Disease Department of Internal Medicine, Health Care Center Bitterfeld, Bitterfeld-Wolfen, Germany

    Peter Lanzer

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this entry

Cite this entry

Bassas, L., Resmini, E. (2015). Hormone Replacement Therapy with Testosterone and the Vascular System. In: Lanzer, P. (eds) PanVascular Medicine. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-37078-6_173

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-37078-6_173

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-37077-9

  • Online ISBN: 978-3-642-37078-6

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation